Supplementary Data from Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
Darren C. Phillips(AbbVie (United States)), Susan E. Morgan-Lappe(Abbott Fund), D. L. Widomski(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), Nandini Rudra-Ganguly(AbbVie (United States)), Li Zhou(AbbVie (United States)), Enrico L. DiGiammarino(AbbVie (United States)), Yu Xiao, Zhihong Liu(Chinese Academy of Sciences), Xin Lu(Center for Genomic Science), Nan Xu(Quzhou University), Haichao Zhang(Abbott Fund), Vivek C. Abraham(AbbVie (United States)), Stephen K. Tahir(Abbott Fund), Larry R. Solomon(AbbVie (United States)), Bruce A. Trela(AbbVie (United States)), John Xue(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States))
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541